Clinical and laboratory features at the time of diagnosis in patients with MDS classified according to the FAB subtypes
| . | MDS (all patients) . | RA . | RARS . | RAEB . | RAEB-T . | CMML . |
|---|---|---|---|---|---|---|
| Patients = N (%) | 431 | 142 (33) | 47 (11) | 92 (21) | 51 (12) | 99 (23) |
| Median age, y (range) | 73 (31-92) | 73 (31-88) | 76 (39-92) | 74 (39-89) | 69 (31-87) | 74 (48-91) |
| Sex ratio (M/F) | 0.87:1 | 0.82:1 | 0.38:1 | 0.88:1 | 0.76:1 | 1.41:1 |
| Neutrophils × 109/μL (median; range) | 2.0 (0.1-46.8) | 2.4 (0.1-13.4) | 2.6 (0.5-15.1) | 1.5 (0.1-21.1) | 1.0 (0.1-8.7) | 2.9 (0.1-46.8) |
| Hemoglobin g/dL (median; range) | 9.5 (3.6-16.7) | 9.7 (3.6-14.7) | 9.2 (4.7-13.3) | 9.4 (4.8-15.1) | 8.5 (4.6-14.8) | 10.5 (5.2-16.7) |
| Platelets × 109/μL (median; range) | 110 (4-763) | 149 (12-494) | 230 (4-597) | 104 (5-763) | 62 (4-320) | 92 (5-602) |
| LDH (120-240 U/L) (median; range) | 226 (81-2312) | 218 (105-990) | 195 (102-624) | 213 (116-816) | 246 (81-914) | 268 (106-2312) |
| Bone marrow blasts (%) | 7 (0-29) | 1 (0-4) | 1 (0-4) | 10 (5-20) | 25 (22-29) | 15 (0-29) |
| Available cytogenetics = N (%) | 273 (63) | 83 (58) | 22 (47) | 67 (73) | 34 (67) | 67 (68) |
| Normal karyotype (%) | 47 | 45 | 55 | 48 | 38 | 52 |
| IPSS (% patients) | ||||||
| Low | 23 | 47 | 50 | 0 | 0 | 8 |
| Intermediate-1 | 35 | 49 | 50 | 37 | 0 | 23 |
| Intermediate-2 | 23 | 4 | 0 | 48 | 7 | 51 |
| High | 19 | 0 | 0 | 15 | 93 | 18 |
| Median survival (mo) | 30 | 66 | 73 | 15 | 9 | 24 |
| Transition to AML (%) | 36 | 25 | 16 | 38 | 66 | 46 |
| Median preleukemic duration (mo) | 58 | 101 | NR | 24 | 5 | 24 |
| . | MDS (all patients) . | RA . | RARS . | RAEB . | RAEB-T . | CMML . |
|---|---|---|---|---|---|---|
| Patients = N (%) | 431 | 142 (33) | 47 (11) | 92 (21) | 51 (12) | 99 (23) |
| Median age, y (range) | 73 (31-92) | 73 (31-88) | 76 (39-92) | 74 (39-89) | 69 (31-87) | 74 (48-91) |
| Sex ratio (M/F) | 0.87:1 | 0.82:1 | 0.38:1 | 0.88:1 | 0.76:1 | 1.41:1 |
| Neutrophils × 109/μL (median; range) | 2.0 (0.1-46.8) | 2.4 (0.1-13.4) | 2.6 (0.5-15.1) | 1.5 (0.1-21.1) | 1.0 (0.1-8.7) | 2.9 (0.1-46.8) |
| Hemoglobin g/dL (median; range) | 9.5 (3.6-16.7) | 9.7 (3.6-14.7) | 9.2 (4.7-13.3) | 9.4 (4.8-15.1) | 8.5 (4.6-14.8) | 10.5 (5.2-16.7) |
| Platelets × 109/μL (median; range) | 110 (4-763) | 149 (12-494) | 230 (4-597) | 104 (5-763) | 62 (4-320) | 92 (5-602) |
| LDH (120-240 U/L) (median; range) | 226 (81-2312) | 218 (105-990) | 195 (102-624) | 213 (116-816) | 246 (81-914) | 268 (106-2312) |
| Bone marrow blasts (%) | 7 (0-29) | 1 (0-4) | 1 (0-4) | 10 (5-20) | 25 (22-29) | 15 (0-29) |
| Available cytogenetics = N (%) | 273 (63) | 83 (58) | 22 (47) | 67 (73) | 34 (67) | 67 (68) |
| Normal karyotype (%) | 47 | 45 | 55 | 48 | 38 | 52 |
| IPSS (% patients) | ||||||
| Low | 23 | 47 | 50 | 0 | 0 | 8 |
| Intermediate-1 | 35 | 49 | 50 | 37 | 0 | 23 |
| Intermediate-2 | 23 | 4 | 0 | 48 | 7 | 51 |
| High | 19 | 0 | 0 | 15 | 93 | 18 |
| Median survival (mo) | 30 | 66 | 73 | 15 | 9 | 24 |
| Transition to AML (%) | 36 | 25 | 16 | 38 | 66 | 46 |
| Median preleukemic duration (mo) | 58 | 101 | NR | 24 | 5 | 24 |
LDH, lactate dehydrogenase; NR, not reached.